Since Froedtert Hospital adopted the test, the mortality rate for sepsis patients has decreased by 42% and hospital length of ...

Data Published in Journal PLOS ONE Demonstrates Investigational IntelliSep test may Provide Useful Prognostic Information for Patients with Suspected Infection SAN FRANCISCO--(BUSINESS WIRE)--Cytovale ...

A new study from Froedtert Hospital, an academic medical center in Milwaukee, shows that patients with suspected infection who received the IntelliSep(R) rapid sepsis test had 42% lower mortality and ...

SAN FRANCISCO--(BUSINESS WIRE)--Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the ...

AI-enabled IntelliSep uses sophisticated high-speed cameras and microfluidics to analyze the reaction of white blood cells from a patient showing signs and symptoms of sepsis. Using a standard blood ...

Medical diagnostics company Cytovale has announced the publication of data that shows its sepsis diagnostics tool IntelliSep has a negative predictive value of 97.5%. The FDA-cleared IntelliSep ...

The new diagnostic test determines the level of activation of a patient's immune system, which reflects whether the patient has sepsis. A Baton Rouge, Louisiana-based hospital has generated positive ...

“Sepsis is more deadly than heart attack and stroke combined — in fact it’s the deadliest, costliest, and arguably most complex condition facing hospitals today.” IntelliSep was cleared by the FDA in ...

Cytovale Inc. has posted a feverish run of wins lately. The company gained U.S. FDA clearance for its Intellisep rapid test for sepsis in January 2023, raised $84 million in a series C in November and ...

SAN FRANCISCO, Jan. 9, 2025 /PRNewswire/ -- Cytovale ®, a commercial-stage medical diagnostics company, today celebrated a monumental year that catapulted it to lead the emerging sepsis diagnostics ...